A number of Examine Outcomes of Kelun-Biotech’s TROP2-ADC SKB264 (sac-™T) at 2024 CSCO Congress By Investing.com
CHENGDU, China, Sept. 28, 2024 /PRNewswire/ -- From September 25th to 29th,…
Kremlin says it should examine Zelenskiy’s ‘victory plan’ if particulars are launched formally By Reuters
MOSCOW (Reuters) - The Kremlin stated on Monday it might examine what…
Pfizer Presents Optimistic Information from Section 2 Examine of Ponsegromab in Sufferers with Most cancers Cachexia By Investing.com
Examine met main endpoint of change from baseline in physique weight for…
TD Cowen maintains Purchase on Seres, cites optimistic examine information By Investing.com
On Thursday, TD Cowen expressed continued confidence in Seres Therapeutics (NASDAQ:), sustaining…
Longboard Prescription drugs Broadcasts Optimistic Interim Evaluation Outcomes from the Open-Label Extension (OLE) of the Part 1b/2a PACIFIC Examine Evaluating Bexicaserin in Members with Developmental and By Investing.com
Bexicaserin achieved an general median seizure discount of 57.7% in countable motor…
China’s lending to Africa rises for first time in seven years, research reveals By Reuters
By Duncan Miriri NAIROBI (Reuters) -Chinese language lenders accredited loans value $4.61…
Yunovia Pronounces IND Approval by the MFDS to Provoke Section 1 MAD Examine for the Small Molecule GLP-1 Agonist By Investing.com
SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D…
Research outcomes from section 1 research with exidavnemab printed in The Journal of Medical Pharmacology By Investing.com
STOCKHOLM, Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA…
Senhwa Biosciences receives US FDA Examine Might Proceed letter for the Part I/II examine of Silmitasertib (CX-4945) together with chemotherapy in kids and younger adults with relapsed refractory s By Investing.com
TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc.…
Scotiabank sees ‘deep worth’ in Sage Therapeutics inventory regardless of research setback By Investing.com
On Wednesday, Scotiabank adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE), decreasing the…
